ArticleTargeted oncology2024

A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.

James R Berenson et al.PubMed ↗Publisher ↗

No numbers read from the abstract.